Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medical indication for ERCP~* first ERCP in the Patient~* signed informed consent forms for ERCP and MagPEP trial~Exclusion Criteria:~* privious ERCP~* hypersensitivity to study medication or similar substances~* participation in another clinical trial during the last 4 weeks~* addictive disorders~* women who are pregnant or breastfeeding~* unwillingness or inability to comply with study protocol~* acute pancreatitis~* renal insufficiency of stage 4 or higher~* active hyperthyreosis~* symptomatic bradycardia (\<35/min)~* known history of Myasthenia gravis~* AV bock \> first degree or other bradycardic disorders of conductivity~* liver cirrhosis Child C~* coagulation disorder~* urinary stone diathesis (calcium magnesium ammonium phosphate stones)~* patients who are not able to provide informed consent~* intake of magnesium during the last 14 days~* intake of calcium antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Magnesium (Type: EXPERIMENTAL): Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate).
- Placebo (NaCl 0,9%) (Type: PLACEBO_COMPARATOR): Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~To each infusion 10 ml NaCl 0.9% (Placebo) will be added .

Based on this trial design, predict the completion outcome and termination type (if applicable).